Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS To Lay Off 4,300 in Restructuring Bid | Contract Pharma

What are you searching for?

Sign in
Breaking News

BMS To Lay Off 4,300 in Restructuring Bid

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb has publicized the details of its restructuring initiative as it works to become a “next-generation BioPharma company.” With the aim of generating $1.5 billion in annual pre-tax savings by 2010 (the year that top-seller Plavix loses patent protection), the company plans to fire 4,300 staffers — approximately 10% of its workforce — in the process of reducing its roster of manufacturing sites by 50% by the end of 2010 and reducing the number of brands in its “mature products portfolio” by 2011.

Costs for the firings and closings are projected to be between $900,000 and $1.1 million. Said chief executive officer James M. Cornelius, “It is difficult to see our valued colleagues leave the company, but right-sizing our workforce across all areas is critical to achieving our productivity goals and enhancing the competitive position of the company. While we are reducing headcount in certain functions, we will continue to invest in R&D, biologics and commercialization talent.”

The company plans to sell its medical imaging business and is also looking at “strategic alternatives” for its ConvaTec (ostomy supplies) and Mead Johnson (baby nutritionals) units.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters